Overview
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers.
Eligibility
Inclusion Criteria -
- Is a healthy adult volunteer
Exclusion Criteria -
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN)
- Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection
- Has an estimated glomerular filtration (eGFR) of <90 mL/min/1.73m^2 at screening
- Is not willing to comply with the contraceptive requirements during the study period
Note: other protocol defined inclusion / exclusion criteria apply